Kentucky - Quality Improvement Implementation Lung Cancer Screening (QUILS™) Implementation

Timothy Mullett330 enrolled

Overview

This is an optimization pathway for lung cancer screening programs. Enrolled programs will undergo an audit for elements associated with improved quality and retention of patients in the screening process. A feedback report is delivered to identify priorities for process improvement.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

330

Conditions

Lung Cancer Screening

Interventions

QUILS SystemOTHER

Implementation initiative involving statewide coalition engagement surveys, interviews, educational outreach, and collaborative activities designed to improve awareness, coordination, policy support, and implementation of equitable and high-quality lung screening programs.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants in Lung Cancer Screening Program, including physicians, nurses, administrators and other staff responsible for the conduct of the program. * Willing to participate in the QUILS Index Assessment Survey process * Willing to participate in the QUILS Audit Feedback presentations Willing to participate in formative evaluation interviews Exclusion Criteria: * Unwilling to participate in the QUILS Index Assessment Survey process * Unwilling to participate in the QUILS Audit Feedback presentations * Unwilling to participate in formative evaluation interviews

Locations (17)

King's Daughter's Medical Center

Ashland, Kentucky, United States

RECRUITING

Outcomes

Primary Outcomes

Change in Quality Improvement Lung Cancer Screening (QUILS) Index Assessment Score

The QUILS Index Assessment is a program-level measure of lung cancer screening implementation quality. Scores range from 0 to 95, with a higher score indicating higher quality implementation of lung cancer screening practices. The outcome measure is the change in total QUILS Index score from Baseline to 12 months.

Time frame: One year following study start up and initial assessment.

Central Contacts

Joseph Alexander, MD

CONTACT

8593230892 joseph.alexander@uky.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.